Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.29 USD | -0.96% | +5.61% | +22.81% |
Financials (USD)
Sales 2024 * | 43.32M | Sales 2025 * | 19.08M | Capitalization | 515M |
---|---|---|---|---|---|
Net income 2024 * | -82M | Net income 2025 * | -106M | EV / Sales 2024 * | 6.42 x |
Net cash position 2024 * | 237M | Net cash position 2025 * | 129M | EV / Sales 2025 * | 20.2 x |
P/E ratio 2024 * |
-6.45
x | P/E ratio 2025 * |
-5.22
x | Employees | 76 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.61% |
Latest transcript on Fulcrum Therapeutics, Inc.
1 day | -0.96% | ||
1 week | +5.61% | ||
Current month | +5.61% | ||
1 month | +10.53% | ||
3 months | -25.18% | ||
6 months | +67.47% | ||
Current year | +22.81% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Sapir
CEO | Chief Executive Officer | 57 | 23-06-30 |
Alan Musso
DFI | Director of Finance/CFO | 62 | 23-08-06 |
Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Geraghty
BRD | Director/Board Member | 69 | 16-07-18 |
Director/Board Member | 70 | 16-11-30 | |
James Collins
BRD | Director/Board Member | 58 | 16-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.02% | 2 M€ | -.--% | ||
0.00% | 9 M€ | +9.52% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 8.29 | -0.96% | 260,870 |
24-06-06 | 8.37 | -3.24% | 334,212 |
24-06-05 | 8.65 | +6.27% | 311,769 |
24-06-04 | 8.14 | -0.49% | 498,903 |
24-06-03 | 8.18 | +4.20% | 928,002 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.81% | 515M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- FULC Stock